LGVN vs. VINC, BIVI, IPA, COCP, BIOR, BCTX, JAN, APRE, RNXT, and ONCT
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Vincerx Pharma (VINC), BioVie (BIVI), ImmunoPrecise Antibodies (IPA), Cocrystal Pharma (COCP), Biora Therapeutics (BIOR), BriaCell Therapeutics (BCTX), JanOne (JAN), Aprea Therapeutics (APRE), RenovoRx (RNXT), and Oncternal Therapeutics (ONCT). These companies are all part of the "pharmaceutical preparations" industry.
Vincerx Pharma (NASDAQ:VINC) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
Vincerx Pharma has a net margin of 0.00% compared to Vincerx Pharma's net margin of -2,129.24%. Longeveron's return on equity of -261.83% beat Vincerx Pharma's return on equity.
Vincerx Pharma received 12 more outperform votes than Longeveron when rated by MarketBeat users. However, 88.89% of users gave Longeveron an outperform vote while only 64.52% of users gave Vincerx Pharma an outperform vote.
Vincerx Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
Longeveron has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
In the previous week, Longeveron had 2 more articles in the media than Vincerx Pharma. MarketBeat recorded 2 mentions for Longeveron and 0 mentions for Vincerx Pharma. Longeveron's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.
44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 22.9% of Vincerx Pharma shares are held by insiders. Comparatively, 19.1% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Vincerx Pharma presently has a consensus target price of $5.00, indicating a potential upside of 602.25%. Longeveron has a consensus target price of $12.00, indicating a potential upside of 1,053.85%. Given Vincerx Pharma's higher possible upside, analysts clearly believe Longeveron is more favorable than Vincerx Pharma.
Summary
Vincerx Pharma beats Longeveron on 8 of the 14 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
